Prognostic Factors in Children with HLH Investigated
|
By LabMedica International staff writers Posted on 27 Oct 2016 |

Image: A photomicrograph of a bone marrow showing stromal macrophages containing numerous red blood cells in their cytoplasm from a patient with hemophagocytic lymphohistiocytosis (Photo courtesy of Nephron).
Hemophagocytic lymphohistiocytosis (HLH) is a rare disease characterized by a rapidly fatal hematological disorder usually associated with malignancies and severe infections and it presents with prolonged high fever that could not be controlled by antibiotics.
Other manifestations of HLH are hepatosplenomegaly, cytopenia, widespread infiltration with lymphocytes, and benign-looking histiocytes with hemophagocytosis in the bone marrow, liver, spleen, or lymph nodes. Early diagnosis and combined treatment can effectively control this life-threatening disease.
Scientists at the Guangdong Medical College (Shenzhen, People’s Republic of China) carried out a retrospective analysis on HLH from January 1, 2000, to November 30, 2013. Of the 56 pediatric patients, 35 were boys and 21 were girls with a median age of 4.5 years (range: four months to 12 years) at the onset of HLH. The median duration before diagnosis of HLH was 1.5 weeks (range: one week to six weeks). The most common clinical symptoms observed were fever (100%), hepatomegaly or splenomegaly (95.24%), and pancytopenia (100%).
The team found that characteristic laboratory values presented with increased ferritin (64.29%), triglycerides (78.6%), transaminases (81%), bilirubin (67.5%), lactate dehydrogenase (95.2%), and decreased fibrinogen (61.9%), sodium (40.5%), and potassium (30.9%). Bone marrow aspiration showed hemophagocytosis in 48 cases (85.7%). Among the clinical and laboratory features analyzed, high lactate dehydrogenase (LDH) of greater than 2,000 U/L, high bilirubin of greater than 2 mg/mL, and younger age less than 2 years old at the time of diagnosis indicated worst outcome.
Anemia was observed in 39 patients (five cases with hemoglobin level less than 90 g/L, 27 cases less than 60–89 g/L, seven cases less than 30–59 g/L), neutropenia (neutrophil count less than 1.5×109/L) in 28 patients (22 cases less than 0.5–1.0×109/L, and five cases less than 0.5×109/L, and thrombocytopenia (platelet count less than 100×109/L) in 35 patients (33 cases with platelet count less than 20–99×109/L and two cases with platelet count less than 20×109/L). Examination of bone marrow aspiration showed hemophagocytosis in 48 (85.7%) patients.
The authors concluded that the etiology of HLH is complicated and early diagnosis is difficult. The level of LDH and bilirubin may predict the severity of HLH and depending on the clinical presentation, individualized therapy is needed for different patients. The study was published on October 11, 2016, in the Journal of Blood Medicine.
Related Links:
Guangdong Medical College
Other manifestations of HLH are hepatosplenomegaly, cytopenia, widespread infiltration with lymphocytes, and benign-looking histiocytes with hemophagocytosis in the bone marrow, liver, spleen, or lymph nodes. Early diagnosis and combined treatment can effectively control this life-threatening disease.
Scientists at the Guangdong Medical College (Shenzhen, People’s Republic of China) carried out a retrospective analysis on HLH from January 1, 2000, to November 30, 2013. Of the 56 pediatric patients, 35 were boys and 21 were girls with a median age of 4.5 years (range: four months to 12 years) at the onset of HLH. The median duration before diagnosis of HLH was 1.5 weeks (range: one week to six weeks). The most common clinical symptoms observed were fever (100%), hepatomegaly or splenomegaly (95.24%), and pancytopenia (100%).
The team found that characteristic laboratory values presented with increased ferritin (64.29%), triglycerides (78.6%), transaminases (81%), bilirubin (67.5%), lactate dehydrogenase (95.2%), and decreased fibrinogen (61.9%), sodium (40.5%), and potassium (30.9%). Bone marrow aspiration showed hemophagocytosis in 48 cases (85.7%). Among the clinical and laboratory features analyzed, high lactate dehydrogenase (LDH) of greater than 2,000 U/L, high bilirubin of greater than 2 mg/mL, and younger age less than 2 years old at the time of diagnosis indicated worst outcome.
Anemia was observed in 39 patients (five cases with hemoglobin level less than 90 g/L, 27 cases less than 60–89 g/L, seven cases less than 30–59 g/L), neutropenia (neutrophil count less than 1.5×109/L) in 28 patients (22 cases less than 0.5–1.0×109/L, and five cases less than 0.5×109/L, and thrombocytopenia (platelet count less than 100×109/L) in 35 patients (33 cases with platelet count less than 20–99×109/L and two cases with platelet count less than 20×109/L). Examination of bone marrow aspiration showed hemophagocytosis in 48 (85.7%) patients.
The authors concluded that the etiology of HLH is complicated and early diagnosis is difficult. The level of LDH and bilirubin may predict the severity of HLH and depending on the clinical presentation, individualized therapy is needed for different patients. The study was published on October 11, 2016, in the Journal of Blood Medicine.
Related Links:
Guangdong Medical College
Latest Hematology News
- New Marker Helps Detect Aggressive Multiple Myeloma Earlier
- New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
- AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
- Blood Test Helps Predict Short-Term Mortality After Severe Heart Attack
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
- Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Channels
Clinical Chemistry
view channel
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read moreMolecular Diagnostics
view channel
New Test Delivers Four Prenatal Genetic Screens from One Blood Sample
Prenatal genetic screening often requires multiple tests, blood draws, and follow-up appointments, delaying access to clinically relevant information. Early, consolidated insights may help clinicians coordinate... Read more
Multiplex PCR Test Differentiates Four Causes of Ulcerative Skin Lesions
Vesicular and pustular skin lesions can stem from multiple viral pathogens, complicating timely diagnosis and management. Sequential single-pathogen testing can miss infections when the causative agent... Read more
Blood Test Guides Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer
Radium-223 dichloride is a bone-targeted radiopharmaceutical therapy that improves overall survival and quality of life for many patients with metastatic castration-resistant prostate cancer (mCRPC), but... Read moreImmunology
view channel
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read more
AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
Tempus AI, Inc. (Chicago, IL, USA) has entered into a definitive agreement to acquire Personalis, Inc. (Fremont, CA, USA), expanding its capabilities in molecular residual disease (MRD) testing and cancer... Read more




.jpg)



